Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 457 | 80 | 374 |
| Samples | 232 | 55 | 174 |
| Peptides | 190 | 34 | 157 |
Function
KPNA5 · Karyopherin subunit alpha 5
The transport of molecules between the nucleus and the cytoplasm in eukaryotic cells is mediated by the nuclear pore complex (NPC) which consists of 60-100 proteins and is probably 120 million daltons in molecular size. Small molecules (up to 70 kD) can pass through the nuclear pore by nonselective diffusion; larger molecules are transported by an active process. Most nuclear proteins contain short basic amino acid sequences known as nuclear localization signals (NLSs). KPNA5 protein belongs to the importin alpha protein family and is thought to be involved in NLS-dependent protein import into the nucleus. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000368564 | O15131 | 243 | 189 |
| ENST00000356348 | O15131 | 212 | 180 |
| ENST00000697696 | A0A8V8TLL2* | 2 | 2 |
Gene Properties
Recurrent Mutations
All 189 amino-acid changes on canonical ENST00000368564 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KPNA5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KPNA5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Endometrial Carcinoma | 3/42 7% | 11/612 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Melanoma | 3/210 1% | 23/1899 1% |
| Plasma Cell Myeloma | 3/44 7% | 1/305 0% |
| Neuroendocrine Tumour | 7/154 5% | 0/577 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 14/1592 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Gastric Carcinoma | 1/74 1% | 13/1809 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Colorectal Carcinoma | 5/143 4% | 18/3239 1% |
| Other Solid Cancers | 0/94 0% | 11/1515 1% |
| Other Sarcomas | 4/69 6% | 1/699 0% |
| Esophageal Carcinoma | 2/23 9% | 3/769 0% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 2/810 0% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 6/1390 0% |
| Ovarian Carcinoma | 3/109 3% | 2/998 0% |
| Breast Carcinoma | 4/144 3% | 11/3264 0% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Meningioma | 1/3 33% | 0/252 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Hepatocellular Carcinoma | 0/46 0% | 7/2210 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Pancreatic Carcinoma | 3/89 3% | 1/1611 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 6/2550 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
Mutation Distribution
Where KPNA5 is mutated · all tissues, split by cell line vs tissue
How many mutations in KPNA5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 457 mutations in KPNA5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|